Form 4: Royalty Pharma CFO Sells Shares Under 10b5-1 Plan

Royalty Pharma's EVP & CFO, Terrance P. Coyne, sold 69,582 Class A Ordinary Shares for approximately $38.42 per share under a pre-arranged 10b5-1 plan.

Summary

• Terrance P. Coyne, Executive Vice President and Chief Financial Officer of Royalty Pharma plc (RPRX), reported the sale of 69,582 Class A Ordinary Shares.
• The transactions occurred on January 2, 2026, and were executed pursuant to a Rule 10b5-1 trading plan adopted on August 8, 2025.
• The shares were sold at a weighted average price of $38.4157 per share, with individual transaction prices ranging from $38.29 to $38.64.
• The total value of the shares sold is approximately $2,672,900.
• Following these transactions, Mr. Coyne beneficially owns 550,928 Class A Ordinary Shares directly and indirectly through various entities and family accounts.
• Additionally, Mr. Coyne and family vehicles control limited partnership interests in RPI US Partners 2019, LP, exchangeable into 6,448,180 Class A Ordinary Shares.
• Mr. Coyne also holds Class E Ordinary Shares of Royalty Pharma Holdings Ltd (RPH) exchangeable into 1,807,277 Class A Ordinary Shares, which are subject to vesting conditions.

Sentiment

Score: 5

Explanation: The filing reports a routine insider sale executed under a pre-arranged 10b5-1 trading plan, which is a common practice for executives to manage their equity holdings and is not typically indicative of new company-specific positive or negative developments.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Minimal impact on shareholders as this is a routine, pre-scheduled insider transaction and does not signal a change in company fundamentals or management's long-term outlook.

Key Dates

Recommendation

The sale by EVP & CFO Terrance P. Coyne was conducted under a Rule 10b5-1 trading plan, which was established well in advance of the transaction date. Such pre-scheduled sales are common for executives for personal financial planning and diversification and typically do not reflect a change in the company's operational performance or future prospects. Therefore, this filing alone does not warrant a change in investment recommendation.

Keywords

Royalty Pharma, RPRX, Terrance Coyne, insider sale, Form 4, 10b5-1 plan, executive transaction, Class A Ordinary Shares